Savant Capital LLC Has $1.57 Million Stock Position in Zoetis Inc. $ZTS

Savant Capital LLC boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 58.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,716 shares of the company’s stock after purchasing an additional 3,952 shares during the period. Savant Capital LLC’s holdings in Zoetis were worth $1,568,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ZTS. Halbert Hargrove Global Advisors LLC boosted its position in Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after purchasing an additional 144 shares during the last quarter. NewSquare Capital LLC raised its stake in shares of Zoetis by 69.1% during the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after purchasing an additional 85 shares in the last quarter. Financial Consulate Inc. bought a new stake in shares of Zoetis during the 3rd quarter worth approximately $39,000. SJS Investment Consulting Inc. boosted its holdings in shares of Zoetis by 1,606.3% in the 3rd quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock valued at $40,000 after buying an additional 257 shares during the last quarter. Finally, TruNorth Capital Management LLC bought a new position in shares of Zoetis in the third quarter valued at $42,000. 92.80% of the stock is owned by institutional investors.

Zoetis Price Performance

ZTS stock opened at $127.28 on Tuesday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64. The business has a 50-day simple moving average of $123.96 and a two-hundred day simple moving average of $136.01. Zoetis Inc. has a 52-week low of $115.25 and a 52-week high of $177.00. The company has a market capitalization of $56.09 billion, a P/E ratio of 21.43, a price-to-earnings-growth ratio of 2.20 and a beta of 0.96.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be paid a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.7%. Zoetis’s dividend payout ratio is presently 35.69%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ZTS. Bank of America cut shares of Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 target price on the stock. in a report on Monday, December 15th. Piper Sandler reaffirmed a “neutral” rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. JPMorgan Chase & Co. reduced their price target on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Morgan Stanley set a $160.00 target price on shares of Zoetis in a report on Thursday, December 18th. Finally, HSBC set a $140.00 price objective on shares of Zoetis in a research report on Wednesday, December 10th. Five analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $152.45.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.